University of Ioannina
Μοριακοί καρκινικοί δείκτες σε όγκους του παχέος εντέρου, καρκίνο του μαστού και προστατικές νεοπλασίες: ανίχνευση γυμνού DNA και RNA στο πλάσμα, μεθυλίωση και ο ρόλος των πρωτεϊνών 14-3-3
Abstract
dc:descriptionScope: In this study we examined several molecular markers in cancer patients and in normal individuals. The present study was focused in the study of molecular markers in the diagnosis of various neoplasias such as brain tumors, prostate, breast and gastric cancers. The markers tested were: 1. RNA markers: a. PSMA mRNA in blood samples ofprostate cancer patients. b. CEA mRNA in blood samples ofprostate and gastric cancer patients. c. 14-3-3σ mRNA in patients with lung, breast and prostate cancer as well as in leukemias. 2. DNA markers: a. DNA quantification in plasma samples of patients with prostate, breast and gastric cancer. b. Méthylation status in the promoter region ofthe following genes: I. MGMT II. 14-3-30 III. GSTP1 IV. RASSFla V. ATM. The méthylation pattern ofthese genes was tested in tissues and/or peripheral blood of cancer patients. Methods: DNA quantification in plasma was performed using real-time PCR and the DNA DipStick™ Kit. We then assessed the méthylation status ofMGMT, 14-3-3o and GSTP1 in plasma DNA using MSP (Methylation-specific PCR) assay, while the méthylation status ofRASSF1A and ATM genes was examined by the MethyLight technology. RT-PCR analysis was used for the detection of PSMA and CEA RNA. Results: DNA molecular markers were detected in increased percentages of cancerpatients. Important rates of detection were observed for the quantification of DNA in plasma and for the méthylation status of GSTP1, RASSF1A και ATM genes. 58.3% of newly diagnosed prostate cancer patients and 26.7% of prostate cancer patients under therapy had increased plasma DNA levels. Additionally, 48.5% of breast cancer patients showed plasma DNA levels above the cut-off limit. GSTP1 promoter hyperméthylation was detectable in 75% of plasma samples obtained from patients with newly diagnosed prostate cancer and in 36.8% ofpatients under therapy, whereas26% and 14% of the breast cancer patients tested were positive for RASSF1A and ATM méthylation respectively. Detection of RNA molecular markers was found in smaller percentages in the blood of cancer patients. Conclusion: The combination of DNA load and genes promoter méthylation statuscould be a new non invasive approach for early detection of both prostate and breast cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2006
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulou, Eirini
- Παπαδοπούλου, Ειρήνη
Subjects
dc:subject × 19- Δεσοξυριβοζονουκλεϊκό οξύ
- Ριβοζονουκλεϊκό οξύ
- Ειδικό μεμβρανικό προστατικό αντιγόνο
- Καρκινοεμβρυικό αντιγόνο (CEA)
- O6-μεθυλ-γουανικό-DNA μεθυλοτρανσφεράση
- Ειδική για μεθυλίωση PCR
- DNA
- RNA
- PSMA
- Prostate specific membrane antigen
- PSA
- CEA
- MEMT
- GSTP1
- Methylation specific PCR
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20457